POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).

How it works

Potassium chloride dissociates to potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Replacement therapy corrects hypokalemia and prevents potassium deficiency.

What the body does with it

Metabolism	Potassium is not metabolized; it is excreted primarily by the kidneys via distal tubular secretion, with minor fecal and sweat losses.
Excretion	Renal: >90% as potassium ions, with small fecal loss; no biliary elimination.
Half-life	Not applicable (endogenous ion); distribution half-life ~1-1.5 h with normal renal function.
Protein binding	None (free ion).
Volume of Distribution	0.5-1.0 L/kg (total body water); distribution follows body water compartments.
Bioavailability	Oral: 90-100% (well absorbed); not administered via other routes for systemic effect.
Onset of Action	IV: Immediate; Oral: 30-60 min.
Duration of Action	IV: As long as infusion continues; Oral: Sustained-release forms: 6-8 h.

Classification & Brands

Dosing & administration

10-20 mEq/h IV, not exceeding 20 mEq/h; concentration ≤ 0.2 mEq/mL. Typical total daily dose 40-100 mEq, depending on serum potassium.

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce dose by 50%. GFR <30 mL/min: avoid or use with extreme caution (max 20 mEq/day) due to risk of hyperkalemia.
Liver impairment	No specific adjustment required, but monitor serum K+ closely in cirrhosis or ascites due to potential for hyperkalemia from concurrent medications or acid-base disturbances.
Pediatric use	0.5-1 mEq/kg/dose IV, max 1-2 mEq/kg/day; infusion rate ≤0.5-1 mEq/kg/h, concentration ≤0.1 mEq/mL. Use with caution in neonates.
Geriatric use	Start at lower end of adult dosing (10-20 mEq/day), infuse at slow rate (≤10 mEq/h), monitor renal function and serum K+ frequently due to age-related renal decline and increased sensitivity to hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).

Breastfeeding	Potassium is naturally present in breast milk; supplementation with potassium chloride does not significantly increase milk potassium levels. M/P ratio not established. Considered compatible with breastfeeding when maternal serum potassium is monitored and maintained within normal range.
Teratogenic Risk	Potassium chloride is a normal physiological constituent; no teratogenic effects are reported at usual therapeutic doses. However, hyperkalemia during pregnancy may cause fetal arrhythmias or death. First trimester: No known teratogenic risk. Second and third trimesters: Risk of fetal hyperkalemia if maternal levels are elevated; avoid excessive dosing.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injections should be administered only in carefully diluted solutions via slow intravenous infusion. Rapid infusion may cause fatal hyperkalemia and cardiac arrest. Concentrated solutions must be diluted before use.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal failure with oliguria or anuria","Untreated Addison's disease","Acute dehydration","Heat cramps","Patients with conditions that cause potassium retention (e.g., potassium-sparing diuretics, ACE inhibitors)"]

Clinical Precautions

Precautions

["Monitor serum potassium levels and electrocardiogram during therapy","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia (e.g., diabetes, adrenal insufficiency)","Avoid in patients with severe burns or massive tissue trauma due to risk of hyperkalemia","May cause local irritation if extravasation occurs"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Potassium is not metabolized; it is excreted primarily by the kidneys via distal tubular secretion, with minor fecal and sweat losses.
Excretion	Renal: >90% as potassium ions, with small fecal loss; no biliary elimination.
Half-life	Not applicable (endogenous ion); distribution half-life ~1-1.5 h with normal renal function.
Protein binding	None (free ion).
Volume of Distribution	0.5-1.0 L/kg (total body water); distribution follows body water compartments.
Bioavailability	Oral: 90-100% (well absorbed); not administered via other routes for systemic effect.
Onset of Action	IV: Immediate; Oral: 30-60 min.
Duration of Action	IV: As long as infusion continues; Oral: Sustained-release forms: 6-8 h.

Classification & Brands

Dosing & administration

10-20 mEq/h IV, not exceeding 20 mEq/h; concentration ≤ 0.2 mEq/mL. Typical total daily dose 40-100 mEq, depending on serum potassium.

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce dose by 50%. GFR <30 mL/min: avoid or use with extreme caution (max 20 mEq/day) due to risk of hyperkalemia.
Liver impairment	No specific adjustment required, but monitor serum K+ closely in cirrhosis or ascites due to potential for hyperkalemia from concurrent medications or acid-base disturbances.
Pediatric use	0.5-1 mEq/kg/dose IV, max 1-2 mEq/kg/day; infusion rate ≤0.5-1 mEq/kg/h, concentration ≤0.1 mEq/mL. Use with caution in neonates.
Geriatric use	Start at lower end of adult dosing (10-20 mEq/day), infuse at slow rate (≤10 mEq/h), monitor renal function and serum K+ frequently due to age-related renal decline and increased sensitivity to hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER).

Breastfeeding	Potassium is naturally present in breast milk; supplementation with potassium chloride does not significantly increase milk potassium levels. M/P ratio not established. Considered compatible with breastfeeding when maternal serum potassium is monitored and maintained within normal range.
Teratogenic Risk	Potassium chloride is a normal physiological constituent; no teratogenic effects are reported at usual therapeutic doses. However, hyperkalemia during pregnancy may cause fetal arrhythmias or death. First trimester: No known teratogenic risk. Second and third trimesters: Risk of fetal hyperkalemia if maternal levels are elevated; avoid excessive dosing.